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A B S T R A C T
BACKGROUND Porphobilinogen deaminase, the third enzyme in the haem synthetic 
process -mainly expressed in the erythrocytes and liver - has a key role in the patho-
genesis of the acute porphyrias.
DESIGN AND RESULTS We studied the effect of cirrhosis or cholestasis on this enzyme 
activity and found that:
1. Erythrocyte porphobilinogen deaminase was significantly increased (p=0.0003) in 27 
patients with non-alcoholic liver cirrhosis (19.89±6.65 μmoles/h.l) and 24 patients with 
extrahepatic cholestasis (20.69±11.17 μmoles/h.l) as compared to 30 controls (12.77±4.76 
μmoles/h.l). Its activity was positively correlated to the prothrombin time in both patient 
groups and negatively to the alkaline phosphatase in the cholestasis group.
2. Erythrocyte porphobilinogen deaminase of controls significantly increased when 
their plasma was substituted by that of patients with cholestasis (p<0.001) or cirrhosis 
(p=0.05), although it remained lower than that of the latter. No change was observed 
in samples from patients with cirrhosis or cholestasis when their plasma was substituted 
by that of controls.
3. In 8 rabbits, cholestasis produced by ligation of the common bile duct significantly 
increased porphobilinogen deaminase both in the erythrocytes (from 30.26±10.33 
to 48.87±15.82 nmoles/h.l, p=0.002) and the liver (from 13.27±4.79 to 17.68±5.42 
nmoles/h.g, p=0.035). In 8 sham-operated rabbits erythrocyte porphobilinogen de-
aminase also increased (from 29.60±9.85 to 33.32±12.23 nmoles/h.l, p=0.016), but 
to a significantly lower degree than that of the “cholestatic” group (111.10±10.95 % 
versus 167.96±41.64% p=0.006) while the hepatic enzyme remained unchanged (from 
13.40±3.85 to 13.83±7.21 nmoles/h.g, p=0.80).
4. In 5 patients with cholestasis the mean hepatic PBG-D activity was higher than in 
the 5 controls (12.63±3.24 versus 9.64±1.17 nmoles/h.g), although not significantly 
higher (p=0.11).
CONCLUSION PBG-D activity is considerably increased in liver cirrhosis and clinical 
or experimental cholestasis. It seems probable that plasma factors may play a role in 
this effect by inducing PBG-D activity.
ORIGINAL ARTICLE
1st Department of Internal Medicine, 
“Elpis” General Hospital, Athens, 
Greece and 2nd Department of Internal 
Medicine, Research Institute and 
Diabetes Center, Athens University, 
Attikon Hospital, Athens, Greece
HOSPITAL CHRONICLES 2007, 2(2): 52–57
Address for correspondence:
A.G. Yalouris
3 P. Tsaldari street,  
Ag. Paraskevi 153 43, Greece
KEy wORDS: Cirrhosis, Cholestasis,  
δ-aminolevulinic acid synthetase, 
porphobilinogen deaminase
Submitted: 23-07-07,  
Accepted: 29-08-07
HOSPITAL CHRONICLES 2(2), 2007
53
I N T R O D U C T I O N
Haem is synthesized through a complex pathway involving 
eight enzymes [1]. Decreased activity of any of these enzymes 
-except for the first one, δ-aminolevulinic acid synthetase 
(ALA-S) - results in the accumulation of some by-products 
of the metabolic procedure and, thus, in the pathogenesis of 
the porphyrias [2]. These uncommon metabolic disorders 
are classified either as acute and non-acute, according to the 
presence of neurologic symptoms, or as erythropoietic and 
hepatic, according to the tissue where the metabolic defect 
predominates. In most cases, ALA-S is secondarily induced, 
thus further increasing the accumulation of by-products.
Porphobilinogen deaminase (PBG-D) is the third enzyme 
of the haem synthetic pathway and the second in increasing 
order of activity after ALA-S. It is genetically deficient in 
acute intermittent porphyria and relatively insufficient in 
most other acute porphyrias [1]. Several drugs and chemicals 
are known to affect ALA-S activity and this knowledge is 
of important clinical significance. On the contrary, little is 
known about factors affecting PBG-D activity and it seems 
to be unresponsive to any intervention. Some decades ago, 
Blum et al [3] reported that erythrocyte PBG-D activity was 
increased in a group of patients with chronic hepatic diseases, 
mainly of alcoholic etiology. The aim of the present study was 
to further investigate this finding.
M E T H O D S
The whole study was performed in four phases:
F I R S T  P H A S E
Eighty-one subjects - all with a good nutritional status, 
a mean daily alcohol consumption during the last year no 
more than 10 g, and normal creatinine values were included 
in this phase. They were classified in three groups (I-III) as 
follows:
Group I (controls): Thirty healthy subjects (16 male/14 
female, mean age 54.3 yr) who were not taking any medica-
tion.
Group II (cirrhotic): Twenty-seven patients with non-al-
coholic liver cirrhosis (17 male/10 female, mean age: 61.7 yr). 
Four of them had also developed hepatocellular cancer. A 
coexisting malignancy was excluded in the remaining 23 pa-
tients by a negative liver ultrasonography (in most cases also 
by a computed tomography) and a normal α-fetoprotein value. 
Seventeen patients (13 male, 4 female) were HBsAg-positive 
(3 of them were also HCV-positive), 7 patients (4 male, 3 fe-
male) were only HCV-positive, 2 patients (both female) had 
autoimmune hepatitis and in 1 female patient the etiology of 
cirrhosis was unknown.
Group III (cholestatic): Twenty-four patients with extra-
hepatic bile duct obstruction (14 male/10 female, mean age: 
57.2 yr) due to a bile stone in 18 and to pancreatic cancer in 
6. In some of them, vitamin K was parenterally administered. 
They all had no anaemia.
In all studied subjects, erythrocyte PBG-D activity was 
measured in whole blood (haemolysed with the addition of a 
0.2% Triton-X-100 solution) according to the method by With 
and Pedersen [4]. The results are expressed as micromoles of 
uroporphyrinogen synthesised per liter of red blood cells in 1 
hour. In the patients of groups II and III, serum total bilirubin, 
alanine aminotransferase, alkaline phosphatase, albumins, total 
cholesterol and prothrombin time -expressed as international 
normalised ratio (INR)- were also measured. In most of the 
studied subjects a reticulocyte count was also measured.
S E C O N D  P H A S E
It was performed in 15 subjects -five from each group- 
randomly selected among those included in the first phase. 
Eight ml of blood were taken from one subject of each group 
and the plasma was separated by a refrigerated centrifuge. 
The erythrocytes were twice washed with an isotonic KCl 
solution and then blood samples were “restored” by mixing 
1 ml of plasma with 1 ml of erythrocytes in the following 
combinations:
“normal” plasma/“normal” erythrocytes (No/No)
“cirrhotic” plasma/“cirrhotic” erythrocytes (Ci/Ci)
“cholestatic” plasma/“cholestatic” erythrocytes (Ch/Ch)
“normal” plasma/“cirrhotic” erythrocytes (No/Ci)
“normal” plasma/“cholestatic” erythrocytes (No/Ch)
“cirrhotic” plasma/“normal” erythrocytes (Ci/No)
“cholestatic” plasma/“normal” erythrocytes (Ch/No).
All samples were immediately haemolysed (with the ad-
dition of a 0.2 % Triton-X-100 solution) and remained for 
30 minutes in room temperature. Then erythrocyte PBG-D 
activity was measured as previously. Results were expressed 
as percentage of the No/No value.
T H I R D  P H A S E
Sixteen male white rabbits were randomly divided in two 
equal groups (A, B). In the morning of the operation day, blood 
was taken from an ear vein to measure serum bilirubin (total, 
conjugated), alkaline phosphatase and erythrocyte PBG-D 
activity. After that the rabbits were operated as follows, using 
morphine and ketamine for anaesthesia:
Group A: In these animals after laparotomy the common 
bile duct was ligated and a liver specimen weighing approxi-
mately 0.5 gr was excised.
Group B: In these animals laparotomy and liver biopsy 
were also performed but without ligation of the common 
bile duct.
Hepatic PBG-D activity was measured in the liver speci-
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expressed as nanomoles of uroporphyrinogen synthesised per 
1 gr of liver tissue in 1 hour. Three days after the operation the 
animals were sacrificed. Blood samples and liver specimens 
were taken to repeat the same measurements.
F O U R T H  P H A S E
Ten patients who were operated in the hepatobiliary region 
were included in this phase after giving their informed consent. 
Five of them underwent cholecystectomy for gallstones without 
cholestasis (non-cholestatic group). The other 5 had obstructive 
jaundice due to a common bile duct stone (cholestatic group). 
Since barbiturates -and possibly other drugs- may affect PBG-
D activity [5], anaesthesia was obtained in all 10 patients by 
the use of the same drugs (thiopental, midazolam, isoflurane, 
fentanyl and vecuronium). PBG-D activity was measured in 
a liver specimen excised during the operation.
S T A T I S T I C A L  A N A L y S I S
One-tailed analysis of variance, including the Bonferroni 
t-test, Student’s t-test for paired and unpaired observations as 
well as univariate and multivariate regression analysis were 
used for the statistical evaluation of our results.
R E S U L T S
F I R S T  P H A S E  (table I, figure 1)
Patients with either cirrhosis (p<0.005) or cholestasis 
(p<0.01) had a significantly higher PBG-D activity than the 
controls (F=8.91, p=0.0003). There was not a significant 
difference of the enzymic activity between cirrhotic patients 
with or without hepatocellular cancer (p= 0.90) or between 
patients with cholestasis due to a bile stone or to pancreatic 
cancer (p=0.75). The reticulocyte count was 1.78  0.63 % in 
17 of the controls, 1.40  0.38 % in 24 of the cirrhotic patients 
and 1.77  0.88 % in 18 patients with cholestasis. These values 
TABLE I. Erythrocyte PBG-D activity in controls and 
patients (in μmoles/h.l)
number mean ± SD
Controls 30 12.77 ± 4.76
Cirrhosis (total) 27 19.89 ± 6.65
Cirrhosis (no cancer) 23 19.50 ± 1.92
Cirrhosis (plus cancer) 4 19.96 ± 7.20
Cholestasis (total) 24 20.69 ± 11.17
Cholestasis (bile stone) 18 20.25 ± 11.40
Cholestasis (cancer) 6 22.00 ± 11.38
FIGURE 1. Erythrocyte porphobilinogen deaminase activity 
(mean, standard deviation) in controls and patients with cirrhosis 
or cholestasis.
did not differ significantly among the three groups (F= 2.23, 
p= 0.12).
In the cirrhotic patients, univariate analysis showed that 
PBG-D values were significantly correlated positively to those 
of INR (r=0.8641, p<0.001) and negatively to those of serum 
albumins (r=-0.8125, p<0.001). Multiple regression analysis 
showed (R=0.8972, F=13.76, p<0.0001) this correlation to 
be significant only with INR (p=0.0037). In the cholestatic 
patients univariate analysis showed a significant negative 
correlation of PBG-D to alkaline phosphatase (r=-0.9196, 
p<0.001) while multiple regression analysis revealed (R=0.9520, 
F=27.38, p<0.0001) a significant correlation negatively to the 
alkaline phosphatase (p<0.0001) and positively to the INR 
(p=0.031).
S E C O N D  P H A S E  (table II)
The substitution of their homologous plasma with that of 
normal subjects did not actually change erythrocyte PBG-D 
TABLE II. PBG-D activity in the mixed samples of the 
second phase (expressed as percentage of the No/No* 
value)
mean ± SD
Ci/Ci* 146.80 ± 22.99
Ch/Ch* 148.60 ± 13.70
No/Ci* 143.80 ± 21.22
No/Ch* 145.40 ± 16.82
Ci/No* 117.20 ± 14.17
Ch/No* 124.60 ± 5.03
* their meaning is explained in the text
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TABLE III. Pre- and post-operative values in cholestatic and sham-operated rabbits (mean  standard deviation)
bilirubin bilirubin con-alkaline erythrocyte liver
total 
(mg/dl)







preoperative 0.24±0.12 0.13±0.05 178.25±32.82 30.26±10.33 13.27±4.79
postoperative 6.54±4.07 4.61±3.06 378.38±216.25 48.87±15.82 17.68±5.42
SHAM-OPERATED
preoperative 0.330.12 0.150.09 180.3841.83 29.609.85 13.403.85
postoperative 0.310.11 0.120.06 167.3835.23 33.3212.23 13.837.21
FIGURE 2. Erythrocyte porphobilinogen deaminase activity 
(mean, standard deviation) pre-and post-operatively in cholestatic 
and sham-operated rabbits.
activity in samples from patients with cirrhosis (t=0.21, p=0.84) 
or cholestasis (t=0.33, p=0.75). On the contrary, PBG-D activity 
of normal subjects significantly increased when their plasma 
was substituted by that of patients with either cirrhosis (t=2.71, 
p=0.05) or cholestasis (t=10.94, p<0.001). However, even 
increased, the enzymic activity remained significantly lower 
than that of the respective blood samples from patients with 
cirrhosis (Ci/Ci versus Ci/No: t=2.45, p=0.04) or cholestasis 
(Ch/Ch versus Ch/No: t=3.68, p=0.014).
T H I R D  P H A S E  (table III, figure 2)
In group A, PBG-D activity significantly increased after 
bile duct ligation both in the erythrocytes (t=4.87, p=0.002) 
and the liver (t=2.62, p=0.035). There was also a consider-
able increase in total and conjugated bilirubin and alkaline 
phosphatase. Τhe simple laparotomy of group B caused a 
smaller but also significant increase in the erythrocytic (t=3.18, 
p=0.016) but not in the hepatic PBG-D (t=0.26, p=0.80). Bi-
lirubin and alkaline phosphatase values remained unchanged. 
The percent increase of erythrocyte PBG-D in group A was 
significantly higher than in group B (167.96±41.64 % versus 
111.10±10.95%, t=3.74, p=0.006). No significant correlation 
of the PBG-D activity increase to that of bilirubin or alkaline 
phosphatase was found.
F O U R T H  P H A S E
The mean hepatic PBG-D activity in patients with cholesta-
sis was higher than in those of the non-cholestatic group 
(12.63±3.24 versus 9.64±1.17 nmoles/h.g). However, the dif-
ference was not statistically significant (t=1.94, p=0.11).
D I S C U S S I O N
Although PBG-D has a key role in most acute porphyrias 
[1], little is known about factors that may affect its activity. In 
order to further investigate the aforementioned observation 
by Blum et al. [3] -later confirmed by Kaczynski et al. [6] - we 
performed the present study. We initially measured erythrocyte 
PBG-D activity in non-alcoholic patients since alcohol is known 
to affect per se haem synthesis [7]. We found it significantly 
increased both in the patients with cirrhosis (mean increase 
55.76%) and in those with extrahepatic cholestasis (mean in-
crease 62.02%) as compared to normal controls. We did not 
exclude from the study cirrhotic patients with coexistence of 
hepatocellular cancer since a previous study [6] showed that 
it does not affect PBG-D activity. This was confirmed in our 
study too. The etiology of cholestasis (benign or malignant 
cause of obstruction) did not seem to affect the increase in 
enzymic activity.
In the cirrhotic group we found a significant positive cor-
relation of PBG-D to the INR and a possible negative one 
to the serum albumins. Since malnourished patients were 
excluded from the study both, INR and serum albumins level 
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levels [9]. In our study, although all patients were jaundiced, 
bilirubin values were not significantly correlated to those of 
PBG-D. In a few experiments (unpublished data), we added 
chemically pure bilirubin to the hemolysate from normal blood 
samples and 30 minutes later we measured PBG-D activity. The 
aimed concentration of 10 mg/dl of blood could not be achieved 
because of the low water solubility of bilirubin. Nevertheless, 
the enzymic activity was moderately decreased.
The increase of PBG-D activity in the patients with cirrhosis 
or cholestasis may be due either to increased synthesis or to 
direct induction of the enzyme. The findings of the second phase 
of our study (cross-incubations) indicate that some factor(s) 
present in the serum of patients with cirrhosis or cholestasis 
can directly increase PBG-D activity of normal erythrocytes 
and not induce its synthesis since mature erythrocytes do not 
contain DNA. The observed increase was lower than that in 
the erythrocytes of the respective patients. This finding may 
be due either to the fact that this effect is time dependant 
and could not be achieved completely in the relatively short 
preincubation period (30 minutes) or to the fact that there is 
also an increased production of PBG-D in these patients. The 
erythrocytes from patients with either cirrhosis or cholestasis 
kept their increased PBG-D activity when their homologous 
plasma was substituted by that of controls. This finding indicates 
that the “inducing effect” of these conditions, if achieved, is 
maintained even in the absence of plasma factors during the 
incubation period.
A crucial question for us was whether liver PBG-D activ-
ity is also increased since acute porphyrias are all mainly of 
hepatic origin. We found that cholestasis produced in rabbits 
by bile duct ligation caused an increase of PBG-D whose mean 
value was higher than that of the sham-operated animals by 
56.86% in the erythrocytes and 43.60% in the liver. A similar 
increase (31.02%) in liver PBG-D was found in our patients 
(fourth phase) although the difference from the controls was not 
statistically significant, possibly because of the small number 
of cases. So it seems that in both patients and experimental 
animals, cholestasis increases PBG-D activity and this effect 
is possibly more pronounced in the erythrocytic than in the 
hepatic enzyme. It must be noted that Piper et al. [10] have 
also noted an increase in PBG-D activity by nearly 40% in rats 
with experimental cholestasis. The reason why the enzymic 
activity was - to a significantly lesser degree- also elevated in 
the red cells of sham-operated animals is unclear. One may 
speculate that it was due to the operative stress or to the drugs 
used for anaesthesia -although we did not use drugs known to 
affect haem synthesis.
In conclusion, PBG-D activity is considerably increased 
in cholestasis and cirrhosis and plasma factors seem to play a 
role in it. Future studies may reveal these factors and possibly 
offer a novel approach to the management of patients with 
acute porphyria.
can be accepted as reliable indices of the severity of hepatic 
failure. So it may be suggested that by-products, not sufficiently 
metabolised by the liver as normally, or factors involved in the 
pathogenesis of liver injury are responsible for the increase in 
the enzymic activity. In the second case, one would expect a 
good correlation of PBG-D activity to the alanine aminotrans-
ferase, which, however, was not found in our study.
In the cholestatic group PBG-D activity was also increased. 
However, it was negatively correlated to the alkaline phos-
phatase, an index of the severity of cholestasis. Thus, patients 
with mild cholestasis had higher PBG-D values than those 
with a severe one. A possible explanation for this paradox is 
that the increase in PBG-D activity is indirectly produced 
through changes in liver function due to the cholestasis, but if 
cholestasis is severe enough it can reverse this effect possibly 
by a direct inhibitory action on the same enzyme. In favour 
of that possibility is the positive correlation of PBG-D to the 
INR, also observed in this group, although we must mention 
that in patients with cholestasis, INR may be increased not only 
due to affected liver function but also due to malabsorption of 
vitamin K, because of the cholestasis. Some of our patients, 
however, were already receiving vitamin K parenterally, which 
could reverse the effect of cholestasis on INR.
Could the effect of cholestasis be attributed to retention 
of substances as bilirubin or bile acids? Kohasi et al [8] found, 
that, in rats, bilirubin -a molecule with considerable similarity 
to hydroxymethylbilane, the product of the reaction catalysed by 
PBG-D - was a reversible, non-competitive inhibitor of purified 
rat liver PBG-D whereas several bile acids had no effect on it. 
With regard to humans, only indirect information is offered 
by a study in patients with Gilbert’s syndrome according to 
which PBG-D activity was normal although bilirubin was high 
enough and did not change when bilirubin returned to normal 
FIGURE 3. Liver porphobilinogen deaminase activity (mean, 
standard deviation) pre-and post-operatively in cholestatic and 
sham-operated rabbits.
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